Impact of brown rice-specific γ-oryzanol on epigenetic modulation of dopamine D2 receptors in brain striatum in high-fat-diet-induced obesity in mice
Overeating of dietary fats causes obesity in humans and rodents. Recent studies in humans and rodents have demonstrated that addiction to fats shares a common mechanism with addiction to alcohol, nicotine and narcotics in terms of a dysfunction of brain reward systems. It has been highlighted that a high-fat diet (HFD) attenuates dopamine D2 receptor (D2R) signalling in the striatum, a pivotal regulator of the brain reward system, resulting in hedonic overeating. We previously reported that the brown rice-specific bioactive constituent γ-oryzanol attenuated the preference for an HFD via hypothalamic control. We therefore explored the possibility that γ-oryzanol would modulate functioning of the brain reward system in mice.
Male C57BL/6J mice fed an HFD were orally treated with γ-oryzanol, and striatal levels of molecules involved in D2R signalling were evaluated. The impact of γ-oryzanol on DNA methylation of the D2R promoter and subsequent changes in preferences for dietary fat was examined. In addition, the effects of 5-aza-2′-deoxycytidine, a potent inhibitor of DNA methyltransferases (DNMTs), on food preference, D2R signalling and the levels of DNMTs in the striatum were investigated. The inhibitory effects of γ-oryzanol on the activity of DNMTs were enzymatically evaluated in vitro.
In striatum from mice fed an HFD, the production of D2Rs was decreased via an increase in DNA methylation of the promoter region of the D2R. Oral administration of γ-oryzanol decreased the expression and activity of DNMTs, thereby restoring the level of D2Rs in the striatum. Pharmacological inhibition of DNMTs by 5-aza-2′-deoxycytidine also ameliorated the preference for dietary fat. Consistent with these findings, enzymatic in vitro assays demonstrated that γ-oryzanol inhibited the activity of DNMTs.
We demonstrated that γ-oryzanol ameliorates HFD-induced DNA hypermethylation of the promoter region of D2R in the striatum of mice. Our experimental paradigm highlights γ-oryzanol as a promising antiobesity substance with the distinct property of being a novel epigenetic modulator.
KeywordsDNA methylation Dopamine Epigenetics Feeding behaviour Nutrition Obesity Reward Striatum Type 2 diabetes
Dopamine D1 receptor
Dopamine D2 receptor
Signal transducer and activator of transcription 3α
Overeating in obese individuals shares, at least partly, common mechanisms with addiction to alcohol, nicotine and narcotics . As well as the hypothalamic and hormonal regulation of appetite, the brain reward system, in particular dopamine receptor signalling, is closely related to addictive or hedonic feeding behaviour . A previous study in rats showed that knockdown of the striatal dopamine D2 receptor (D2R) by lentivirus-mediated short hairpin interfering RNA rapidly induced addiction-like reward deficits and compulsion-like food seeking . Because of the reduced D2R density, the dorsal striatum is less responsive to food reward compared with lean control groups in obese humans and rodents [3, 4, 5]. In accordance with this notion, the TaqIA allele of the ANKK1 gene locus (encoding DRD2/ankyrin repeat and kinase domain containing 1), which decreases striatal D2R production, is associated with an obese phenotype in humans , while the effects of weight loss after bariatric surgery are associated with elevated striatal D2R density . These data strongly suggest the importance of striatal D2R as a novel therapeutic target for the treatment of obesity. However, some drugs that were developed that acted on the brain reward system caused considerable adverse effects, including serious psychiatric problems, resulting in their eventual withdrawal from clinics .
Epigenetic modifications are critical not only for development and differentiation, but also because they arise as a result of environmental changes, including in diet and lifestyle . DNA methylation is a chief epigenetic event for the stability of gene expression . In rats, maternal exposure to a high-fat diet (HFD) intergenerationally alters DNA methylation within the central reward system in the offspring, leading to overconsumption of HFD by the pups . In particular, DNA methyltransferases (DNMTs) play critical roles in the regulation of both feeding behaviour and physical activity [10, 11], suggesting that DNMTs could be promising therapeutic targets for the therapy of obesity–diabetes syndrome. Importantly, some natural food-derived substances, including caffeic acid and epigallocatechin, are known to act as DNMT inhibitors [12, 13].
We have recently shown that the bioactive, brown rice-specific component γ-oryzanol, a mixture of ferulic acid ester and several phytosterols, attenuates the preference for dietary fat via a decrease in hypothalamic endoplasmic reticulum (ER) stress . In mice and rabbits, orally administered γ-oryzanol was rapidly absorbed from the intestine and distributed mainly to the brain [15, 16]. Taking these findings together, natural food-derived products acting on the central nervous system could be an alternative to safely ameliorate impaired feeding behaviour in obesity. In this context, we tested the hypothesis that γ-oryzanol would alter DNA methylation status in the brain reward system, resulting in an attenuation of the preference for an HFD in mice.
Seven-week-old male C57BL/6J mice obtained from Charles River Laboratories Japan (Kanagawa, Japan) were housed (3–4 per cage) in specific-pathogen-free conditions at 24°C under a 12 h/12 h light/dark cycle. After a week of acclimatisation, 8-week-old mice were weight-matched and divided into two or three groups to undergo each experiment. The mice were allowed free access to food and water. All animal experiments were approved by the Animal Experiment Ethics Committee of the University of the Ryukyus (Nos. 5352, 5718 and 5943).
Administration of γ-oryzanol and 5-aza-2′-deoxycytidine
To evaluate the preference for the HFD, γ-oryzanol (Wako Pure Chemical Industries, Osaka, Japan) was administrated to 8-week-old mice by gavage during the food choice test as previously described [14, 17]. For the other experiments, an HFD (D12079B; Research Diets, New Brunswick, NJ, USA) containing 0.4% γ-oryzanol was manufactured as pellets. The components of the diet are shown in electronic supplementary material (ESM) Table 1. After 12 weeks of feeding, tissue was collected from the striatum and hypothalamus. The daily intake of γ-oryzanol, estimated from the mean food intake of the mice, was approximately 320 μg/g body weight. The doses of γ-oryzanol were determined as previously described . The 5-aza-2′-deoxycytidine (5-aza-dC; Sigma-Aldrich, St Louis, MO, USA) was intraperitoneally injected (0.25 μg/g body weight) three times a week for 12 weeks .
Estimation of preference for dietary fat
To evaluate preferences for dietary fat, food tests provided a choice between chow and HFD (D12450B and D12451; Research Diets) as previously described . The components of diet are shown in ESM Table 1. Briefly, the mice were allowed free access to chow and HFD. Intakes of chow and HFD were measured weekly and analysed for changes in preference for dietary fat. HFD preference was calculated according to the formula: HFD preference = [(HFD intake/total food intake) × 100].
Bisulphite sequencing for DNA methylation
DNA was purified using a DNeasy Blood & Tissue Kit (QIAGEN, Tokyo, Japan). The DNA solution was mixed with freshly prepared 3 mol/l NaOH, incubated at 37°C for 15 min and added to 5.3 mol/l urea, 1.7 mol/l sodium bisulphite and 4.9 mmol/l hydroquinone. The solution was subjected to 15 cycles of denaturation at 95°C for 30 s and incubation at 50°C for 15 min . The bisulphite-treated DNA was purified using MinElute PCR Purification Kit (QIAGEN) and amplified by PCR using a KAPA HiFi HotStart Uracil+ ReadyMix PCR Kit (KAPA Biosystems, Woburn, MA, USA) and primers around the CpG site of the promoter region of D2R. The primer sequences were as follows: forward primer, 5′-GTAAGAATTGGTTGGTTGGAGTTAAAA-3′; reverse primer, 5′-ACCCTACCCTCTAAAACCACAACTAC-3′. Next, the adapter sequences were added and cleaned up using Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA). Samples were then pooled and loaded onto a GS Junior (Roche Diagnostics, Tokyo, Japan) for sequencing according to the manufacturer’s protocol. The methylation level was expressed as the percentage of methylated cytosines in all cytosines residues.
DNMT activity assay
The DNMT enzymatic activity assay was performed using an EpiQuik DNA Methyltransferase Activity/Inhibition Assay Kit (Epigentek Group, Brooklyn, NY, USA) and EPIgeneous Methyltransferase Assay kit (Cisbio Japan, Chiba, Japan) according to the manufacturer’s protocols.
To assess the inhibitory activity of each compound on DNA methylation, the formation of S-adenosyl-l-homocysteine (SAH) was measured in the presence of each compound (20 μmol/l for screening assays), S-adenosyl methionine (SAM; 10 μmol/l) and DNMT substrate (4 ng/μl) at 37°C for 90 min. To evaluate the Michaelis–Menten kinetics, DNMT1 (20 μmol/l) was incubated with γ-oryzanol, SAM (5 μmol/l) and the indicated concentration of poly dI-dC at 37°C for 90 min. DNMT3a (100 μmol/l) and DNMT3b (100 μmol/l) were incubated with γ-oryzanol, SAM (5 μmol/l) and the indicated concentration of poly dG·dC at 37°C for 120 min. The assays were performed in quadruplicate. Extracted protein (0.75 mg/ml) was incubated with SAM (5 μmol/l), poly dI-dC (5 μg/ml), and poly dG·dC (5 μg/ml) at 40°C for 120 min, and SAH formation was measured.
Oestrogen-related receptor-γ activity assay
The potential antagonistic activity of γ-oryzanol on the oestrogen-related receptor-γ (ERRγ) was assessed using the Human Estrogen-Related Receptor Gamma Reporter Assay System (INDIGO Bioscience, State College, PA, USA) according to the manufacturer’s protocol. Briefly, non-human mammalian reporter cells constitutively expressing active ERRγ were exposed to the indicated concentrations of each compound for 24 h in triplicate.
This was performed as previously described  with antibodies against D2R (1:500, rabbit), dopamine transporter (DAT; 1:500, rabbit), tyrosine hydroxylase (TH; 1:1000, rabbit) (AB5084P, AB1591P and AB152, Merck Millipore, Billerica, MA, USA), signal transducer and activator of transcription 3α (STAT3α; 1:1000, rabbit), DNMT1 (1:1000, rabbit), DNMT3a (1:1000, rabbit) (nos. 8768, 5032 and 3598; Cell Signaling Technology, Tokyo, Japan), DNMT3b (1 μg/ml, rabbit), ERRγ (1:1000, rabbit) and β-actin (1:10,000, mouse) (ab16049, ab128930 and ab6276; Abcam, Cambridge, MA, USA).
Quantitative real-time PCR
Gene expression was examined as previously described . mRNA levels were normalised to Rn18s (18S rRNA). The primer sets used for the quantitative real-time PCR analyses are summarised in ESM Table 2.
Data are expressed as mean ± SEM. One-way ANOVA and repeated-measures ANOVA followed by multiple comparison tests (Bonferroni–Dunn method) were used where applicable. Student’s t test was used to analyse differences between two groups. Differences were considered significant at p < 0.05.
Pharmacological inhibition of DNMTs by 5-aza-dC attenuated the preference for dietary fat in mice
To examine whether DNA methylation in the promoter region of D2R would alter the preference for dietary fat, the feeding behaviour of 5-aza-dC-treated mice was analysed. As expected, 5-aza-dC significantly increased mRNA and protein levels for D2R in the striatum of HFD-fed mice (Fig. 1b, k, l). On the other hand, there was no effect on levels of Drd1, Th and Slc6a3 (encoding DAT) in the striatum, or on levels of Drd2, Drd1, Th and Slc6a3 in the hypothalamus (Fig. 1c–e, g–m). Whereas vehicle-treated mice preferred the HFD, preference for the HFD was significantly decreased in 5-aza-dC-treated mice (88% of the values for vehicle-treated mice) (Fig. 1n). Consequently, treatment with 5-aza-dC reduced the gain in body weight (Fig. 1o).
γ-oryzanol decreases levels of DNMTs in striatum of HFD-fed mice
In mammals, there are three major DNMTs—DNMT1, 3a and 3b. DNMT1 functions to maintain DNA methylation, while DNMT3a and 3b play a role in facilitating de novo DNA methylation . To explore the potential impact of γ-oryzanol on DNMTs in vivo, we evaluated levels of DNMTs in the brains of HFD-fed mice. Although the HFD per se had no effect on mRNA and protein levels of DNMTs in either the striatum or the hypothalamus, supplementation with γ-oryzanol significantly decreased levels of DNMTs in the striatum but not in the hypothalamus (Fig. 2c–e, g–i, k–n). These data raise the possibility that γ-oryzanol might regulate levels of DNMTs in a striatum-specific manner. In a similar fashion, 5-aza-dC significantly decreased mRNA levels of DNMT3a and 3b preferentially in the striatum (ESM Fig. 1a–d).
To further assess the impact of γ-oryzanol on the activity of DNMTs in vivo, the formation of SAH, a byproduct of DNA methylation and also a potent inhibitor of DNMTs, was evaluated in γ-oryzanol-treated mice fed the HFD. There were no significant changes in SAH formation in either the striatum or the hypothalamus between HFD-fed and chow-fed mice (Fig. 2f, j). Noticeably, γ-oryzanol significantly decreased SAH formation in the striatum (Fig. 2f) but not in the hypothalamus (Fig. 2j), suggesting that γ-oryzanol may suppress the activity of DNMTs in a striatum-specific manner in HFD-fed mice.
Enzymatic analyses on inhibitory properties of γ-oryzanol for DNMTs in vitro
We further investigated the inhibitory properties of γ-oryzanol on DNMTs. The formation of SAH was measured to assess the inhibitory activity of γ-oryzanol on DNMTs in vitro. Data on SAH formation during DNMT-mediated DNA methylation indicate a saturable pattern of Michaelis–Menten kinetics for both the presence and absence of γ-oryzanol (Fig. 4g–i). In DNMT1-mediated DNA methylation, Eadie–Hofstee analysis demonstrated that γ-oryzanol showed no effects on the V max of SAH formation (vehicle, 597 pmol/min; γ-oryzanol 2 μmol/l, 619 pmol/min; γ-oryzanol 20 μmol/l, 608 pmol/min), while γ-oryzanol apparently increased the K m (vehicle, 0.47 μg/ml; γ-oryzanol 2 μmol/l, 0.67 μg/ml; γ-oryzanol 20 μmol/l, 0.89 μg/ml) (Fig. 4j). These results suggest that γ-oryzanol inhibits DNMT1 at least partly in a competitive manner. On the other hand, for DNMT3a- and 3b-mediated DNA methylation, γ-oryzanol decreased the V max of formation of SAH (DNMT3a: vehicle, 85.3 pmol/min; γ-oryzanol 2 μmol/l, 63.1 pmol/min; γ-oryzanol 20 μmol/l, 42.5 pmol/min; DNMT3b: vehicle, 42.3 pmol/min; γ-oryzanol 2 μmol/l; 28.0 pmol/min, γ-oryzanol 20 μmol/l, 15.0 pmol/min) and, similarly, the K m for this reaction (DNMT3a: vehicle, 0.0086 μg/ml; γ-oryzanol 2 μmol/l, 0.0080 μg/ml; γ-oryzanol 20 μmol/l, 0.0058 μg/ml; DNMT3b: vehicle, 0.0122 μg/ml; γ-oryzanol 2 μmol/l, 0.0097 μg/ml; γ-oryzanol 20 μmol/l, 0.0060 μg/ml) (Fig. 4k, l). These results suggest that γ-oryzanol inhibits DNMT3a and 3b at least partly in a non-competitive manner.
γ-oryzanol increases levels of D2R in striatum of HFD-fed mice
The major finding in the present study is that γ-oryzanol acts as a potent DNMT inhibitor in the striatum of mice, thereby attenuating, at least partly, the preference for an HFD via the epigenetic modulation of striatal D2R. In striatum from HFD-fed mice, levels of D2R were significantly decreased, whereas those of D1R, TH and DAT were not changed (Fig. 1b–e, k–m). These data are consistent with the notion that dysregulation of striatal D2R plays a critical role in the perception of food reward when on an HFD, leading to hedonic overconsumption of HFD in obese animals . In the present study, treatment of HFD-fed mice with 5-aza-dC significantly increased levels of striatal D2R (Fig. 1b, k, l) possibly through a reduction in DNA methylation level in the promoter region of D2R (Fig. 1a), and consequently attenuated the preference for dietary fat (Fig. 1n). This finding also supports a critical role of striatal D2Rs in the perception of food reward when on an HFD.
Our in vitro assay demonstrated that the inhibitory activity of γ-oryzanol against DNMTs was apparently stronger than that of its metabolite ferulic acid (Fig. 4d–f), suggesting the importance of the complete structure of γ-oryzanol for its inhibitory action on DNMTs. In HFD-fed mice, our studies suggest that, after oral administration, γ-oryzanol reaches the brain as a complete structure and decreases the levels and activities of DNMTs preferentially in the striatum, with a consequent decrease in DNA methylation in the promoter region of D2R in the striatum. Furthermore, our in vitro studies have demonstrated that γ-oryzanol acts as a partial antagonist against ERRγ, which primarily serves as a positive regulator for DNMT1 production , and consequently decreased the activity of DNMT1 (Fig. 3a). Of note, ERRγ was highly expressed in the striatum but not in the hypothalamus in mice (Fig. 3b). These data suggest that γ-oryzanol has the potential to decrease the mRNA level of DNMT1, at least partly, through the inhibition of ERRγ. In contrast to striatum, γ-oryzanol showed no effect on the level of D2R in hypothalamus from HFD-fed mice (Fig. 5g, k, l).
On the other hand, we demonstrated that γ-oryzanol significantly increased levels of DNMT1 in the hypothalamus but not in the striatum (Fig. 2k, l). It has been shown that STAT3 increases the content of DNMT1 in malignant T-lymphoma cells . Notably, we previously demonstrated that γ-oryzanol significantly increased leptin-induced STAT3 phosphorylation in hypothalamus from HFD-fed mice . It should also be noted that STAT3α was substantially expressed in the hypothalamus but not in the striatum in the mice (Fig. 3e–g). These data tempt us to speculate that the apparent difference in effect of γ-oryzanol on levels of DNMT1 between the hypothalamus and the striatum may be attributed, at least partly, to the region-specific content of STAT3α and ERRγ in the brain of mice (Fig. 3b–g). Collectively, there seems to be a reciprocal pattern of expression of ERRγ and STAT3α between the striatum and the hypothalamus in mice. On the basis of our results, it is therefore reasonable to speculate that in striatum, where ERRγ production is abundant, γ-oryzanol may preferentially decrease the mRNA level and enzyme activity of DNMT1 as a negative regulator of ERRγ. In contrast, in the hypothalamus, where STAT3α production is dominant, γ-oryzanol may preferentially increase levels of DNMT1.
A recent study demonstrated that an attenuation of striatal D2R signalling induced by an HFD dysregulates feeding behaviour , suggesting the potential importance of the inhibition of striatal DNMTs for the treatment of obesity. On the other hand, a previous study demonstrated a possibility that the status of DNA methylation of the melanocortin receptor 4 gene expressed in specific hypothalamic nuclei could modulate transgenerational forms of obesity in agouti viable yellow mice . Although further studies are warranted to elucidate the underlying mechanisms, these studies suggest the importance of tissue-, gene- and sequence-specific DNA methylation in the pathophysiology of HFD-induced obesity.
We recently reported that HFD increased the level of D2R in the pancreatic islets of mice [17, 24]. It is likely that such augmentation is mediated, at least partly, by ER stress and inflammation via NF-κB, because there are several NF-κB-responsive elements in the promoter region of D2R [17, 24]. Furthermore, a recent study has shown that TNF-α and IL-1β increase the level and activity of DNMT1 in adipose tissue from HFD-fed mice . Importantly, the present study demonstrated that HFD induced ER stress and inflammation preferentially in hypothalamus but not in the striatum (Fig. 6). In-depth mechanisms of tissue-, region-, and site- specific DNA methylation and demethylation in our experimental paradigm must await further investigation.
Together with our previous report showing that γ-oryzanol attenuates the preference for an HFD via hypothalamic regulation of ER stress in mice , γ-oryzanol also represents a unique property of ameliorating both hedonic and metabolic dysregulation of feeding behaviour. Because some antiobesity drugs that have been developed are known to cause critical adverse effects , a natural food-based approach toward the brain reward system is anticipated to treat obesity–diabetes syndrome safely . In this paradigm, γ-oryzanol is a promising antiobesity candidate with a distinct property of being an epigenetic modulator.
We are grateful to S. Okamoto (University of the Ryukyus, Japan) for reviewing the manuscript. We thank M. Hirata, H. Kaneshiro, I. Asato and C. Noguchi (University of the Ryukyus, Japan) for secretarial assistance.
Datasets generated and/or analysed during the current study are available from the corresponding author on reasonable requests.
This work was supported in part by Grants-in-Aid from Japan Society for the Promotion of Science (JSPS; KAKENHI Grant Numbers 15K19520 and 24591338), the Council for Science, Technology and Innovation (CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP) ‘Technologies for creating next-generation agriculture, forestry and fisheries’, the Lotte Foundation, the Japan Foundation for Applied Enzymology, New Energy and Industrial Technology Development Organization (NEDO), the Project for Formation of Life Science Network (Pharmaceutical Field) (Okinawa Prefecture, Japan) and the Promotion Project of Medical Clustering of Okinawa Prefecture, Japan, along with a grant from the Okinawa Prefecture for promotion of advanced medicine (Okinawa Prefecture, Japan).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
CK and HM designed the research. CK and TK performed the experiments and analysed the data. TK, CS-O, CT, MT, MM and KA contributed to interpretation of data. CK and HM wrote the manuscript. All authors contributed to data interpretation. All authors joined in revising the manuscript and approved its final version. HM is the guarantor of this work, had full access to all the data and takes full responsibility for the integrity of data and the accuracy of data analysis.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.